8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 19, 2005 (December 19, 2005)

BOSTON LIFE SCIENCES, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	0-6533	87-0277826
(State or Other Jurisdiction of Incorporation	(Commission File Number)	(IRS Employer Identification No.)

85 Main Street, Hopkinton, Massachusetts	01748
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (508) 497-2360

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Entry into a Material Definitive Agreement.

On December 19, 2005, Boston Life Sciences, Inc., a Delaware corporation (the “Company”), entered into Amendment No. 6 to its agreement with MDS Nordion, Inc., dated as of August 9, 2000 (“Amendment No. 6”). Amendment No. 6 extends the term of the agreement to the earlier of (i) the grant by the Food and Drug Administration of the Company’s new drug application for the ALTROPANE^® molecular imaging agent or (ii) December 31, 2006.

A complete copy of Amendment No. 6 is filed herewith as Exhibit 99.1 and is incorporated herein by reference. The foregoing description of the Amendment No. 6 does not purport to be complete and is qualified in its entirety by reference to such exhibit.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit   Number	Description of Exhibit
99.1†	Amendment No. 6 dated as of December 19, 2005 to Agreement between MDS Nordion Inc. and the Company.
†	Confidential treatment requested as to certain portions, which portions are omitted and filed separately with the Securities and Exchange Commission.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Boston Life Sciences, Inc.
Date: December 19, 2005	By:	/s/    KENNETH L. RICE, JR.
		Kenneth L. Rice, Jr.
		Executive Vice President, Finance and Administration and Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
99.1†	Amendment No. 6 dated as of December 19, 2005 to Agreement between MDS Nordion Inc. and the Company.
†	Confidential treatment requested as to certain portions, which portions are omitted and filed separately with the Securities and Exchange Commission.

EX-99.1

Exhibit 99.1

Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Asterisks denote omissions.

447 March Road	Tel 1-613.592.2790
Ottawa, ON K2K 1X8	Fax 1-613.592.6937
Canada

MDS Nordion

Science Advancing Health

Boston Life Sciences, Inc.

85 Main Street

Hopkinton, MA 01748

USA

Dear Sirs:

Re: Amendment #6 to Agreement between MDS Nordion Inc.

(now MDS Nordion, a division of MDS (Canada) Inc.

dated the 9^th day of August, 2000 (the “Agreement”)

Reference is made to the agreement between MDS Nordion Inc. (now MDS Nordion, a division of MDS (Canada) Inc.) and Boston Life Sciences Inc. dated the 9^th day of August 2000 ( the “Agreement”).

In consideration of $1.00 and other valuable consideration the sufficiency of which is hereby acknowledged, the parties desire to further amend the Agreement and extend the term.

1. Section 16.1 of the Agreement shall be amended in its entirety and shall read as follows:

“The term of this Agreement shall commence upon the Effective Date, and unless terminated earlier pursuant to this Agreement, shall expire on the earlier of (i) FDA granting of BLSI’s NDA with respect to Altropane for Parkinson’s Disease or (ii) December 31, 2006”.

2. In addition to the Maximum Batch Size available for purchase as identified in Section 4.1 of the Agreement, BLSI agrees to purchase and MDS Nordion agrees to supply Altropane under the Agreement in accordance with the terms and batch size appearing on the face of MDS Nordion’s Quotation 2005-RQ-0254 (attached) and as amended from time to time. The Terms and Conditions on the second page of the quotation shall not apply.

All other Terms and Conditions in this Agreement shall remain in full force and effect.

The foregoing amendment shall be effective as of the date first written above.

If you agree with the foregoing, please execute this Agreement in the space provided below.

Sincerely,
MDS Nordion
Per:	/s/    GERRY VANTELLINGEN
Name:	Gerry Vantellingen
Title:	Vice President, Products and Services

We agree this 19th day of December, 2005.
Boston Life Sciences Inc.
Per:	/s/    KENNETH L. RICE, JR.

ITEM	DESCRIPTION
1.0	QUOTATION FOR THE SUPPLY OF BATCHES OF ALTROPANE FROM JANUARY 1, 2006 UNTIL DECEMBER 31, 2006.
	Batch Description:	up to 20 shippable doses of Altropane (Note 1)
	Price:	$[**] per dose for the first 15 doses. Minimum price per Batch is $[**]. Minimum monthly total is $[**] including Batches processed in that month.
	Freight Charges:	Prepaid and invoiced at cost. AirNet is recommended and is $165 per shipment.
	Notes:
	1.      An Altropane dose contains 5 mCi of I-123 as of 15:00 hrs. PT., the day after manufacture. Additional product specifications are as outlined in the Agreement between BLSI and MDS Nordion which expires on December 31, 2006.

UNLESS OTHERWISE STATED, PRICES DO NOT INCLUDE ANY TAXES OR DUTY.

THIS QUOTATION IS SUBJECT TO TERMS ON THE FACE AND SECOND PAGE.

SHIPPING SCHEDULE:     As Requested By Customer	DELIVERY:     F.O.B. Vancouver, BC
	CURRENCY:     United States Dollars
TERMS (SEE SECOND PAGE):     Net 30 Days	QUOTATION VALID UNTIL:     2006 December 31

ISSUED ON BEHALF OF MDS NORDION
/S/    COLYN K. STEEVES	COLYN K. STEEVES, SALES NUCLEAR MEDICINE

MDS Nordion Science Advancing Health 447 March Road, P.O. Box 13500 Kanata, Ontario, Canada K2K 1X8 Tel: (613) 592-2790     Fax: (613) 592-7638